Research programme: bone morphogenetic protein activators - Curis

Drug Profile

Research programme: bone morphogenetic protein activators - Curis

Alternative Names: BMP activators; BMP agonists; BMP-7 protein; eptotermin alfa analogues; eptotermin alfa mimetics

Latest Information Update: 19 Jan 2011

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Curis
  • Class Small molecules
  • Mechanism of Action Bone morphogenetic protein activators; Intercellular signalling peptide and protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Kidney disorders; Neurological disorders; Vascular disorders

Most Recent Events

  • 22 May 2007 This research programme is available for licensing worldwide (http://www.curis.com)
  • 19 May 2007 Ortho Biotech Products terminates its worldwide licence to this research programme
  • 12 Dec 2005 Curis and Centocor expanded their collaboration agreement to screen and validate small molecule agonists based on Curis' BMP technology portfolio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top